Who is sponsoring NCT05544877?

NCT05544877 is sponsored by Psychiatrische Dienste Thurgau.

What drugs are being tested in NCT05544877?

Interventions in NCT05544877: Integrated 5-day Gratitude Exercise and Behavioral Activation Program.

What condition does NCT05544877 study?

NCT05544877 studies General Psychopathology, Fatigue, Depressive Disorder, Major.

Is NCT05544877 still recruiting?

NCT05544877 is currently completed. Last updated 26 October 2023.

Last reviewed 2023-10-26 · How we verify

NCT05544877: B2B

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Energetic View on Creativity, Psychopathology and Intelligence: The Brain2Business Study

Completed NA Last updated 26 October 2023

What this trial tests

NA trial testing Integrated 5-day Gratitude Exercise and Behavioral Activation Program in General Psychopathology in 200 participants. Completed in 4 October 2023.

Timeline

19 July 2022

Primary endpoint
29 September 2023

4 October 2023

Quick facts

Lead sponsor	Psychiatrische Dienste Thurgau
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	200
Start date	19 July 2022
Primary completion	29 September 2023
Estimated completion	4 October 2023
Sites	1 location across Switzerland

Drugs / interventions tested

Integrated 5-day Gratitude Exercise and Behavioral Activation Program

Conditions studied

General Psychopathology — all drugs for General Psychopathology →
Fatigue — all drugs for Fatigue →
Depressive Disorder, Major — all drugs for Depressive Disorder, Major →

Sponsor

Psychiatrische Dienste Thurgau

Who can join

18 and older, any sex, with General Psychopathology or Fatigue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The interventional part of the study aims to assess the acute effect of the Brain2Business (B2B) tool on creative thinking (primary objective) in adults with psychological disorders. Additionally, the study assesses the B2B effects on energy-related sensations and metabolism, technique adherence, gratefulness and goal-directed activation (secondary objectives) in adults with and without psychological disorders. The observational part of the study primarily aims to investigate the link between psychopathology, intelligence, energy-related sensations and metabolism validating the "c factor mito-bioenergetics" (CMB) model in a sample of adults with and without psychological disorders.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effort of maintaining the defensive wall: is there a link between defense mechanisms and vitality?
Vandersmissen A, Fissler Plischke P, Filippi M, Wenzel M, et al · · 2026 · PMID 42106684 · DOI 10.1186/s12888-026-08146-2

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05544877 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Psychiatrische Dienste Thurgau
Last refreshed: 26 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05544877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing